Results 41 to 50 of about 452,734 (338)

A promising choice in hypertension treatment: Fixed-dose combinations

Asian Journal of Pharmaceutical Sciences, 2014
Obtaining the target blood pressure level by monotherapy can be challenging currently, especially for the patients who are suffering from other diseases meanwhile.
Xinhuan Wan, Panqin Ma, Xiangrong Zhang
doaj   +1 more source

Prevalence of pregabalin prescribing trends from various outpatient department: A prospective observational study from a tertiary care teaching hospital at South India

National Journal of Physiology, Pharmacy and Pharmacology, 2022
Background: We assessed utilization patterns, profile of diagnoses, and fixed dose combination (FDC) with pregabalin in patients with various indications.
Kanagasanthosh K, Saravana K S, Indra A
doaj   +1 more source

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

Advances in Therapy, 2020
Introduction New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed.
S. Asrani, J. Bacharach, E. Holland, Hayley McKee, Huan Sheng, R. Lewis, C. Kopczynski, T. Heah   +7 more
semanticscholar   +1 more source

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).

Respiratory Medicine, 2020
BACKGROUND The efficacy and safety of once-daily (o.d.) fixed-dose combination of indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF) via Breezhaler® versus concurrent administration of salmeterol/fluticasone (SAL/FLU) twice-daily (b.i.d.)
C. Gessner, O. Kornmann, J. Maspero, R. V. van Zyl-Smit, M. Krüll, Anna Salina, Pritam Gupta, Sebastien Bostel, S. Fucile, L. G. Conde, P. Pfister   +10 more
semanticscholar   +1 more source

Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features

Pharmaceutics
Whilst monotherapy is traditionally the preferred treatment starting point for chronic conditions such as hypertension and diabetes, other diseases require the use of multiple drugs (polytherapy) from the onset of treatment (e.g., human immunodeficiency ...
Christi A. Wilkins, Hannlie Hamman, J. Hamman, J. Steenekamp   +3 more
semanticscholar   +1 more source

DRESS syndrome: a case report

MGM Journal of Medical Sciences, 2021
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare adverse drug reaction. We report a rare case of DRESS syndrome secondary to antitubercular treatment (ATT).
Shreya Gudi, Tushar Kanti Biswas, Sriraj Kane   +2 more
doaj   +1 more source

Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel

Journal of Family Medicine and Primary Care, 2020
Type 2 diabetes mellitus (T2DM) is a progressive disease with multifactorial etiology. The first-line therapy includes monotherapy (with metformin), which often fails to provide effective glycemic control, necessitating the addition of add-on therapy. In
S. Kalra, A. Das, G. Priya, Shreeparna Ghosh, R. Mehrotra, Sambit Das, P. Shah, S. Bajaj, V. Deshmukh, D. Sanyal, S. Chandrasekaran, D. Khandelwal, Ansumali Joshi, T. Nair, Fatimah Eliana, H. Permana, Fariduddin, P. Shrestha, D. Shrestha, Shyaminda Kahandawa, M. Sumanathilaka, A. Shaheed, A. Rahim, A. Orabi, A. al-ani, W. Hussein, Dinesh Kumar, K. Shaikh   +27 more
semanticscholar   +1 more source

Heartbeat: Fixed dose combination drugs for hypertension [PDF]

Heart, 2019
Fixed dose combination (FDC) drugs are standard practice in the treatment of infectious diseases, but their role in chronic non-communicable diseases is unclear. FDC anti-hypertensive drugs are an attractive option to improve compliance by reducing the number of pills taken daily, particularly in elderly patients who generally require more than one ...
Antonio Luiz Ribeiro, Catherine M Otto
openaire   +2 more sources

Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report

Acta Medica Indonesiana, 2017
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse.
Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini   +2 more
doaj   +2 more sources

Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review

Pharmaceutics, 2020
Many patients, especially those with a high pill burden and multiple chronic illnesses, are less adherent to medication. In medication treatments utilizing polypills, this problem might be diminished since multiple drugs are fused into one formulation ...
Ana Baumgartner, Katarina Drame, Stijn Geutjens, Marja Airaksinen   +3 more
doaj   +1 more source